Cardiol Therapeutics says Phase II recurrent pericarditis data for CardiolRx published in JAHA
CRDL•Phase II results for CardiolRx published in JAHA
Cardiol Therapeutics reported publication of Phase II MAvERIC results for CardiolRx in the Journal of the American Heart Association.
- Data showed rapid, sustained reductions in pericarditis pain and inflammation, fewer annual pericarditis episodes, and favorable safety and tolerability.
- Publication supports the pivotal Phase III MAVERIC trial, with enrollment nearing completion.
